Phase 1 dose escalation of H3B-6545, a potential first-in-class Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast… Read More »
Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough… Read More »
Next-generation endocrine therapy exhibits differentiated mechanism of action versus standard-of-care therapies and potently inhibits the ERα pathway H3 Biomedicine’s first… Read More »
Expands potential addressable patient population for H3 Biomedicine’s lead splicing modulator H3B-8800, currently in Phase 1 study for other hematologic… Read More »
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »
Recurrent mutations in the spliceosome are observed in several human cancers, but their functional and therapeutic significance remains elusive. SF3B1,… Read More »
Mutations affecting spliceosomal proteins are the most common mutations in patients with myelodysplastic syndromes (MDS), but their role in MDS… Read More »
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to Liz Melone.